TScan Therapeutics Inc
TCRX
查看详细走势图
0.896USD
-0.035-3.79%
收盘 12/19, 16:00（美东）报价延迟15分钟
50.83M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.79%
5天
-11.32%
1月
-9.08%
6月
-37.80%
今年开始到现在
-70.54%
1年
-69.84%
查看详细走势图
TradingKey TScan Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
TScan Therapeutics Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名112/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
TScan Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
7
位分析师
买入
评级
7.000
目标均价
+600.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
TScan Therapeutics Inc亮点
亮点风险
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
业绩增长期
公司处于发展阶段，最新年度总收入2.82M美元
利润高增长
公司净利润处于行业前列，最新年度总收入2.82M美元
估值高估
公司最新PE估值-0.80，处于3年历史高位
机构减仓
最新机构持股42.06M股，环比减少15.90%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值829.92K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.36
TScan Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
TScan Therapeutics Inc简介
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
公司代码TCRX
公司TScan Therapeutics Inc
CEOMacbeath (Gavin)
网址https://www.tscan.com
常见问题
TScan Therapeutics Inc(TCRX)的当前股价是多少？
TScan Therapeutics Inc(TCRX)的当前股价是 0.896。
TScan Therapeutics Inc的股票代码是什么？
TScan Therapeutics Inc的股票代码是TCRX。
TScan Therapeutics Inc股票的52周最高点是多少？
TScan Therapeutics Inc股票的52周最高点是3.430。
TScan Therapeutics Inc股票的52周最低点是多少？
TScan Therapeutics Inc股票的52周最低点是0.910。
TScan Therapeutics Inc的市值是多少？
TScan Therapeutics Inc的市值是50.83M。
TScan Therapeutics Inc的净利润是多少？
TScan Therapeutics Inc的净利润为-127.50M。
现在TScan Therapeutics Inc(TCRX)的股票是买入、持有还是卖出？
根据分析师评级，TScan Therapeutics Inc(TCRX)的总体评级为买入，目标价格为7.000。
TScan Therapeutics Inc(TCRX)股票的每股收益（EPS TTM）是多少
TScan Therapeutics Inc(TCRX)股票的每股收益（EPS TTM）是-1.121。
相关品种
